Guangdong Zhongsheng Pharmaceutical Co., Ltd.

002317.SZ

002317.SZGuangdong Zhongsheng Pharmaceutical Co., Ltd. CN flag

Shenzhen Stock Exchange

15.68

CNY

-1.19

(-7.05%)

-0.32EPS

-49.00P/E

10.97BMarket Cap

Aug 28Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE100000HW4

Return %

Stock

S&P500

24.35

9.99

6.31

59.68

23.37

94.43

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	1.22	1.51	1.81	2.18	2.25	2.43	2.93	3.11	2.36	3.06	3.32	3.17	2.97	2.98
Basic EPS, GAAP	0.25	0.26	0.31	0.41	0.55	0.52	0.54	0.39	-0.53	0.35	0.4	0.32	-0.36	-0.32
Free Cash Flow per Basic Share	0.09	- -	-0.14	0.16	0.26	0.3	0.23	0.15	-0.02	0.52	-0.25	-0.21	0.13	-0.29
Dividend per Share	0.1	0.12	0.13	0.31	0.14	0.2	0.22	0.25	0.24	0.24	0.23	0.21	0.21	0.21
Book Value per Share	0.82	1.18	1.35	2.06	2.46	2.59	2.92	3.04	2.35	2.51	2.63	2.72	2.13	2.24
Tangible Book Value per Share	2.12	2.26	2.35	1.1	2.77	2.6	2.48	2.73	3.52	3.39	3.48	4.05	3.85	3.96
Basic Weighted Avg Shares	726	722	724	724	753	808	807	815	805	793	805	823	831	826
Sales/Revenue/Turnover	886	1,090	1,309	1,578	1,692	1,964	2,362	2,532	1,896	2,429	2,676	2,611	2,467	2,461
Operating Margin (%)	19.77	16.63	17.07	20.26	25.31	23.46	21.9	19.05	14.82	16.48	14.75	13.48	11.13	11.75
Depreciation Expense	26	30	50	63	68	70	78	98	99	96	100	121	125	- -
Net Income, GAAP	182	188	225	297	414	420	436	318	-427	278	322	263	-299	-268
Effective Tax Rate (%)	14.71	14.04	13	13.53	13.01	13.98	13.89	15.6	- -	11.25	14.38	11.9	- -	70.48
Profit Margin (%)	20.48	17.22	17.16	18.81	24.48	21.39	18.45	12.55	-22.5	11.43	12.03	10.08	-12.12	-10.89
Working Capital	1,212	1,136	1,098	120	1,448	1,376	1,506	1,627	2,312	2,147	2,126	2,945	2,259	2,341
LT Debt	- -	6	- -	- -	- -	- -	348	235	232	313	290	98	- -	- -
Total Equity	1,587	1,743	1,899	2,110	3,424	3,730	3,951	4,134	3,626	3,538	3,816	4,526	4,010	4,094
Return on Invested Capital (%)	9.67	9.21	10.34	12.89	12.76	10.25	9.88	8.32	- -	8.49	7.68	6.19	- -	- -
Return on Capital (%)	33.31	24.5	23.32	21.82	22.54	18.79	16.23	10.67	- -	13.09	13.74	10.15	- -	7.53
Return on Common Equity (%)	33.24	25.92	24.48	24.01	24.77	21.28	19.58	13.14	-19.51	14.31	15.7	12.1	-14.94	-12.94

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.66%	1.05%	-5.48%
Net Income, GAAP	-56.54%	-123.05%	-213.63%
Free Cash Flow	-336.07%	-636.1%	-163.55%
Total Cash Common Dividend	14.79%	-3.55%	-0.34%
Total Equity	9.33%	0.07%	-11.39%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Yong Hong Chen
Full Time Employees: 1,775
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Information Industry Park Dongguan People's Republic of China 523325
IPO Date: Dec 11, 2009
Website: zspcl.com
Similar Companies: SCI Pharmtech, Inc. (4119.TW)
FutureChem Co.,Ltd (220100.KQ)
Synmosa Biopharma Corporation (4114.TWO)
Hainan Haiyao Co., Ltd. (000566.SZ)
OptiNose, Inc. (OPTN)
One World Products, Inc. (OWPC)
Business: Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.

	Sep'24	Dec'24	Mar'25
Total Current Assets	3,261	3,463	3,142
Accounts Receivable, Net	581	533	571
Cash, Cash Equivalents & STI	1,377	1,705	1,196
Inventories	484	441	378
Total Current Liabilities	418	1,203	801
Payables & Accruals	- -	- -	- -
ST Debt	2	826	430
Deferred Revenue	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	2	826	430
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	852	852	852
Market Capitalization	11,627	10,387	9,046

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	1.22	1.51	1.81	2.18	2.25	2.43	2.93	3.11	2.36	3.06	3.32	3.17	2.97	2.98
Basic EPS, GAAP	0.25	0.26	0.31	0.41	0.55	0.52	0.54	0.39	-0.53	0.35	0.4	0.32	-0.36	-0.32
Free Cash Flow per Basic Share	0.09	- -	-0.14	0.16	0.26	0.3	0.23	0.15	-0.02	0.52	-0.25	-0.21	0.13	-0.29
Dividend per Share	0.1	0.12	0.13	0.31	0.14	0.2	0.22	0.25	0.24	0.24	0.23	0.21	0.21	0.21
Book Value per Share	0.82	1.18	1.35	2.06	2.46	2.59	2.92	3.04	2.35	2.51	2.63	2.72	2.13	2.24
Tangible Book Value per Share	2.12	2.26	2.35	1.1	2.77	2.6	2.48	2.73	3.52	3.39	3.48	4.05	3.85	3.96
Basic Weighted Avg Shares	726	722	724	724	753	808	807	815	805	793	805	823	831	826
Sales/Revenue/Turnover	886	1,090	1,309	1,578	1,692	1,964	2,362	2,532	1,896	2,429	2,676	2,611	2,467	2,461
Operating Margin (%)	19.77	16.63	17.07	20.26	25.31	23.46	21.9	19.05	14.82	16.48	14.75	13.48	11.13	11.75
Depreciation Expense	26	30	50	63	68	70	78	98	99	96	100	121	125	- -
Net Income, GAAP	182	188	225	297	414	420	436	318	-427	278	322	263	-299	-268
Effective Tax Rate (%)	14.71	14.04	13	13.53	13.01	13.98	13.89	15.6	- -	11.25	14.38	11.9	- -	70.48
Profit Margin (%)	20.48	17.22	17.16	18.81	24.48	21.39	18.45	12.55	-22.5	11.43	12.03	10.08	-12.12	-10.89
Working Capital	1,212	1,136	1,098	120	1,448	1,376	1,506	1,627	2,312	2,147	2,126	2,945	2,259	2,341
LT Debt	- -	6	- -	- -	- -	- -	348	235	232	313	290	98	- -	- -
Total Equity	1,587	1,743	1,899	2,110	3,424	3,730	3,951	4,134	3,626	3,538	3,816	4,526	4,010	4,094
Return on Invested Capital (%)	9.67	9.21	10.34	12.89	12.76	10.25	9.88	8.32	- -	8.49	7.68	6.19	- -	- -
Return on Capital (%)	33.31	24.5	23.32	21.82	22.54	18.79	16.23	10.67	- -	13.09	13.74	10.15	- -	7.53
Return on Common Equity (%)	33.24	25.92	24.48	24.01	24.77	21.28	19.58	13.14	-19.51	14.31	15.7	12.1	-14.94	-12.94

Year	Q1	Q2	Q3	Q4	FY
2023	747	736	589	539	2,611
2024	641	723	544	559	2,467
2025	634	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	0.17	- -	- -	- -	0.32
2024	0.06	- -	- -	- -	-0.36
2025	0.1	- -	- -	- -	- -

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year